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A B S T R A C T
The WHO analgesic ladder for the treatment of cancer pain provides a three-step sequential approach
for analgesic administration based on pain severity that has global applicability. Nonopioids were
recommended for mild pain, with the addition of mild opioids for moderate pain and strong opioids for
severe pain. Here, we review the evidence for the use of nonopioid analgesic agents in patients with
cancer and describe the mode of action of the main drug classes. Evidence supports the use of
anti-inflammatory drugs such as acetaminophen/paracetamol and nonsteroidal anti-inflammatory
drugs (NSAIDs) for mild cancer pain. Adding an NSAID to an opioid for stronger cancer pain is
efficacious, but the risk of long-term adverse effects has not been quantified. There is limited evidence
to support using acetaminophen with stronger opioids. Corticosteroids have a specific role in spinal
cord compression and brain metastases, where improved analgesia is a secondary benefit. There is
limited evidence for adding corticosteroids to stronger opioids when pain control is the primary
objective. Systematic reviews suggest a role for antidepressant and anticonvulsant medications for
neuropathic pain, but there are methodologic issues with the available studies. Bisphosphonates
improve pain in patients with bony metastases in some tumor types. Denosumab may delay
worsening of pain compared with bisphosphonates. Larger studies of longer duration are required to
address outstanding questions concerning the use of nonopioid analgesia for stronger cancer pain.
J Clin Oncol 32:1677-1690. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Up to 90% of patients with cancer experience pain at
some stage of their cancer journey, with a third rat-
ing the intensity of their pain as moderate to
severe,1-3 and up to half being undertreated.1,4,5 The
WHO analgesic ladder, which provides guidelines
for the treatment of cancer pain, was published in
1986 and updated in 1996.6 The guidelines recom-
mend a sequential three-step approach for analgesic
administration based on pain severity, with nonopi-
oids for mild pain, weak opioids for moderate pain,
and strong opioids for severe pain. In addition to
drug selection based on the severity of the pain and
individualized for the patient, recommendations in-
clude the use of oral medications whenever possible,
with fixed scheduled dosing according to the phar-
macokinetics of the drug rather than on demand
and regular assessment and re-evaluation of the
pain. It is recommended that the drugs used in
step 1 be continued as opioids are added. The
rationale for adding a nonopioid to an opioid is to
add a drug with a different mechanism of action
with the aim of improving analgesic control
and/or reducing opioid requirements and mini-
mizing opioid adverse effects.7
When the WHO guidelines were developed to
address the issue of undertreated pain, there was
limited evidence to inform them. Rather, they were
developed to provide a framework to guide interna-
tional policy for the treatment of cancer pain with
pain relief that was affordable and readily accessible
globally. Despite controversies about whether the
secondstepshouldbeomittedandwhethernonopioid
analgesic agents should be continued once an opioid is
required,theWHOanalgesicladderremainsthemain-
stay of management of cancer pain.8 Individual studies
and systematic reviews that have evaluated the WHO
guidelines have shown that they can control cancer
pain in 45% to 100% of patients.9-11
The most common nonopioid agents used to
treat cancer pain include acetaminophen/paraceta-
mol; anti-inflammatory agents such as nonsteroidal
anti-inflammatory drugs (NSAIDs) and corticoste-
roids; antineuropathic agents, which include tricy-
clic antidepressants and anticonvulsants; and
bisphosphonates. The mode of action of each drug is
outlined in Table 1, and the major studies that have
evaluated their use in people with cancer are out-
lined in Tables 2 to 6.
ACETAMINOPHEN/PARACETAMOL
Acetaminophen (known in some countries as parac-
etamol) is an inexpensive analgesic that is used glob-
ally. Although it was developed over a hundred years
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ago, its mode of action for pain relief has not been fully elucidated. It is
sometimes classified as an NSAID, but its mechanism of action is not
the same.25 Acetaminophen is well tolerated with a good safety profile
at therapeutic doses. In overdose, hepatotoxicity and acute renal tu-
bular necrosis can occur. Patients may be at higher risk of hepatotox-
icity after starvation, fasting, or chronic alcohol abuse, but hepatic
toxicity is rare in doses less than 8 g daily, even in patients with chronic
liver disease.20,26 Serious hypersensitivity reactions to acetaminophen
are extremely rare (Table 2).
Acetaminophen for Acute Pain
Systemic reviews and meta-analyses have shown that acetamin-
ophen is more effective than placebo for acute postoperative pain.33-35
The optimal dose of acetaminophen remains uncertain. A Cochrane
review of 51 studies including 5,762 postoperative participants and
using an end point of 50% total pain relief found that a single dose of
acetaminophen was significantly more effective than placebo, with a
number needed to treat of 3.5 patients (95% CI, 2.7 to 4.8 patients) for
500 mg of acetaminophen, 4.6 patients (95% CI, 3.9 to 5.5 patients) for
600 to 650 mg, and 3.6 patients (95% CI, 3.4 to 4.0 patients) for 975 to
1,000 mg.33 There was no difference in adverse effects in the acetamin-
ophen arms compared with placebo.33 Another Cochrane review
comprising 20 studies and 2,641 patients evaluated oxycodone with
and without acetaminophen for acute postoperative pain; the number
needed to treat for oxycodone 15 mg was 4.6 patients (95% CI, 2.9 to
11 patients) compared with 2.7 patients (95% CI, 2.4 to 3.1 patients)
for oxycodone 10 mg and acetaminophen 650 mg.36
Acetaminophen for Patients With Cancer
There is good evidence that acetaminophen is effective for treat-
ing mild cancer pain.37 There is limited evidence for adding acetamin-
ophen to an opioid, and practice varies globally; patients in Europe
and Australasia generally remain on acetaminophen once opioids are
required, but in North America, acetaminophen is generally discon-
tinued once strong opioids are initiated. A systematic review evaluat-
ing acetaminophen in addition to opioids in five small randomized
controlled trials (RCTs) involving 200 patients with cancer found no
benefit to adding acetaminophen in four of the five studies.38 The
positive study used a cross-over design.28 Patients reported a modest
improvement in pain and overall well-being while on acetaminophen
(1 g every 4 hours five times a day), with a nonsignificant preference
for analgesic control during the period they were on acetaminophen.28
A recent RCT evaluated the efficacy of oxycodone (5 mg)/acetamino-
phen (325 mg) compared with placebo every 6 hours for 3 days for
pain caused by bone metastases in 246 patients already on opioids.32
Although the oxycodone/acetaminophen group had improved pain
relief, less breakthrough pain, and reduced need for rescue pain relief,
the study design does not allow the relative contribution of each agent
in the combination to be determined.
NSAIDS
NSAIDs are a heterogeneous group of drugs that inhibit cyclooxygen-
ase (COX), leading to a reduction of the conversion of arachidonic
acid to thromboxane A2 and prostaglandin synthesis (Table 1).
39
There are two main forms of COX—COX-1 (including a variant
known as COX-3) and COX-2. Although COX-1 is present in most
tissues, COX-2 is mainly expressed in inflamed tissue.39,40 Most
NSAIDs are nonselective inhibitors of COX-1 and COX-2, but newer
agents such as celecoxib have much greater affinity for the COX-2
isoform.40 The selective COX-2 inhibitors are substantially more ex-
pensive than the older nonselective agents.
Adverse Effects
The toxicity profile for NSAIDs includes GI and cardiovascular
effects, hepatotoxicity, and nephrotoxicity, including renal failure
caused by renal vasoconstriction, hypertension, and electrolyte distur-
bances.16,41 The risk of toxicity is increased with higher doses of
NSAIDs and in those with comorbidities and the elderly. Patients with
a history of GI bleeding, an NSAID-related ulcer, Helicobacter pylori
infection, renal or hepatic impairment, or chronic heart failure are at
increased risk of serious toxicity. Concomitant use of an NSAID with
antiplatelet or anticoagulant agents, antihypertensives, glucocorti-
coids, or diuretics has an additive risk of hemorrhage or renal hypo-
perfusion. Prior treatment of H pylori or concomitant use of a
gastroprotectant agent (eg, a proton pump inhibitor) may reduce GI
toxicity in those at higher risk.42 Selective COX-2 inhibitors cause less
GI toxicity than nonselective COX-1 and COX-2 inhibitors,41 but
several large studies have shown an increase in cardiovascular toxicity,
including myocardial infarction and stroke, with the selective COX-2
inhibitor rofecoxib.43,44 This is thought to be a result of a prothrom-
botic effect. Some selective COX-2 inhibitors were withdrawn from
the market in 2004 and 2005 because of this toxicity.44 Celecoxib is one
of the main drugs in this class still in common usage.
NSAIDs in Patients With Cancer
The maximum recommended single dose of an NSAID has been
found to be equivalent in analgesic potency to approximately 5 to 10
mg of parenteral morphine.45,46 A meta-analysis of 25 studies in 1,545
patients with cancer found benefit in all eight studies comparing a
single dose of an NSAID with placebo.46 No significant difference in
analgesic efficacy was found in studies comparing an NSAID with an
NSAID and a weak opioid, but studies were difficult to compare
because of heterogeneity (Table 3).
A Cochrane review found seven studies that compared an
NSAID (excluding acetaminophen) with placebo for cancer pain.54
All studies reported improved efficacy for the NSAID, with no differ-
ence in adverse effects, but all were single-dose studies. Thirteen stud-
ies compared different NSAIDs, but there was no convincing evidence
of benefit for one NSAID over another. Of the 10 studies that com-
pared an NSAID with an opioid, four found the NSAID to be more
effective, whereas two studies showed they were less beneficial. Meta-
analyses of four of the studies found a lack of significant difference in
pain relief but more adverse events in the opioid groups (odds ratio,
0.38; 95% CI, 0.15 to 0.97).45,55-57
Use of an NSAID With an Opioid
Eight studies compared an NSAID versus an NSAID combined
with an opioid; four of these studies found that the NSAID/opioid
combination gave marginally better pain relief. Meta-analysis of six of
the studies showed no significant difference in adverse events.54 The
studies used a mixture of weak and strong opioids, making compari-
son problematic.
Both the Cochrane review54 and a more recent systematic review
incorporating additional studies38 showed a benefit to adding an
Vardy and Agar
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NSAID to a WHO step 3 opioid for cancer pain. Five of the seven
studies found the addition of the NSAID to be efficacious,38 with three
reporting improved pain with the addition of dipyrone58 or
ibuprofen47,58a and two finding a decrease in opioid consumption
with the addition of ketorolac53 or diclofenac.59 Six of the seven studies
reported no significant differences in adverse effects between the
groups, with one study finding more gastric discomfort in the NSAID
plus opioid arm and more constipation in the opioid alone arm.53
There were no marked differences between the different NSAID drugs
in efficacy, although individual responses to NSAIDs and their toxicity
are highly variable.
Most of the acetaminophen and NSAID studies in patients
with cancer had small sample sizes and were of short duration, and
none included selective COX-2 inhibitors. Longer term efficacy
and safety remain unknown, with prevalence and severity of tox-
icities not quantified in patients with cancer. Studies have not been
adequately powered to determine whether NSAIDs or acetamino-
phen are more beneficial for certain types of cancer pain, although




Inflammation has key roles in the pathophysiology of pain, and
animal pain models suggest that corticosteroids can modulate pain
perception.18 Proinflammatory cytokines are involved in the develop-
ment of inflammatory and neuropathic pain, including CNS produc-
tion from immune-competent glial cells.18 Endogenous neurosteroids
in the CNS and peripheral nervous system modulate -aminobutyric
acid, N-methyl-D-aspartate, and ATP/adenosine bisphosphate (P2X)
receptors, all of which play crucial roles in pain regulation.17 Steroid
receptors are present in several neural structures, which may allow
steroids to modulate neural activity and plasticity.17 Sex steroids may
also play a role, with testosterone exerting an analgesic effect and
estrogens exerting both hyperalgesic and analgesic effects.17
Adverse Effects
Corticosteroids have multiple effects and lead to a wide range of
potential short- and long-term adverse effects.19 These include effects
on the stress and immune response, carbohydrate metabolism, pro-
tein catabolism, electrolyte regulation, and behavior.19
Agents and Dose
Commonly used corticosteroids are dexamethasone, methyl-
prednisolone, betamethasone, prednisolone, and prednisone.18 Dex-
amethasone is prescribed most often; it causes less fluid retention than
other corticosteroids because it has less mineralocorticoid effect.17,19
Corticosteroids are used with other analgesics in a broad range of
clinical scenarios, in particular for management of bone and neuro-
pathic pain.17 Corticosteroids are included at each step of the WHO
analgesic ladder, when an anti-inflammatory effect is considered ben-
eficial.17 They also have a role in specific clinical scenarios such as
spinal cord compression, brain metastases, and bowel obstruction,60
where improved analgesia is a secondary benefit from the primary
indication of reduction of peritumoral edema.19 There is no estab-
lished dosing, and the studies that have been undertaken comparing
dose effectiveness have explored outcomes other than pain.61
Efficacy
Despite corticosteroids being used widely to manage cancer pain,
there is limited evidence for their efficacy.17 A recent systematic review
demonstrated a paucity of studies and included four RCTs that ex-
plored the role of corticosteroids when added to standard pain man-
agement.18 One study demonstrated efficacy, and one study did not;
the other two studies did not report pain or analgesic use adequately18
(Table 4).
ANTIDEPRESSANTS AND ANTICONVULSANTS
Neuropathic pain is defined by the International Association for the
Study of Pain as pain caused by a lesion or disease of the somatosen-
sory system. It is present in at least 35% to 40% of patients with cancer
pain.20 Up to 40% of survivors of cancer also report pain at 5 years
after treatment that is often neuropathic in nature.22 Chronic pain that
is related to treatment includes pain caused by postsurgical syndromes
(eg, mastectomy, thoracotomy, postamputation); chemotherapy-
related painful peripheral neuropathy; avascular necrosis of the fem-
oral or humeral head; and radiation-induced plexopathy, myelopathy,
or proctitis.
Opioid analgesia is usually insufficient to achieve good control of
neuropathic pain, and additional agents are required, mainly antide-
pressant and anticonvulsant medications.20,21 Neuropathic pain from
cancer may not share pathophysiologic mechanisms with chronic
nonmalignant causes, but a similar range of drugs is used.21 It is more
common to try opioid analgesia alone before adding an adjuvant for
neuropathic pain in North America, whereas European practice is to
use combination therapy earlier.22
Adverse Effects
The choice of agent is often guided by the importance of
potential adverse effects in an individual patient. For example,
tricyclic antidepressants should be avoided if the patient is at risk of
urinary retention. However, some clinicians choose agents based
on characteristics of the pain.21 The agents are used mostly in
combination with opioids, and adverse effects, in particular psy-
choactive adverse effects, can be synergistic.
Agents and Dose
There is a complex interplay between etiology, pathophysiology,
and symptoms of neuropathic pain, and different pathophysiologic
mechanisms can be responsible for similar symptoms.66 Therefore, if
one agent is not effective, it is reasonable to try another agent that may
mediate benefit through a different component of the involved pain
pathways. When partial response is seen with one agent, some clini-
cians consider combination therapy with an agent from another class,
but there are few data to indicate additional benefit from combination
therapy or to guide the choice of combination.21 These medications
are started usually at a low dose and titrated to a dose where effect is
seen with acceptable toxicity. For example, tricyclic antidepressants
are started at 10 to 25 mg at bedtime and gradually increased every 3 to
7 days in 10- to 25-mg increments, up to doses of 150 mg.21 Gabap-
entin has an effective dose range of 100 to 3,600 mg but is commenced
in low doses of 100 to 300 mg at night.21 Pregabalin doses range from
25 to 600 mg, commencing with 25 to 75 mg at night.21 Available data
suggest that adjuvants improve pain control within 4 to 8 days when
Nonopioid Drugs in the Treatment of Cancer Pain
www.jco.org © 2014 by American Society of Clinical Oncology 1683
Downloaded from ascopubs.org by 138.25.168.22 on August 20, 2017 from 138.025.168.022














































































































































































































































































































































































































































































































































































































































































































































1684 © 2014 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by 138.25.168.22 on August 20, 2017 from 138.025.168.022
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
added to opioids for cancer pain.20 The doses used in the randomized
studies are listed in Table 5.
Efficacy
There have been two recent reviews (one systematic) exploring
the role of pharmacologic therapy of neuropathic cancer pain and
another systematic review of the role of antiepileptic or antidepres-
sants added to opioids for cancer pain.20,21,67 These reviews support a
beneficial effect for antidepressants and anticonvulsants in the treat-
ment of both mixed-type and neuropathic cancer pain, but there are
methodologic issues with the included studies.20,21 These include
poorly defined primary outcome measures and varying doses of con-
comitant opioids.67 In several studies, CIs for outcomes in the inter-
vention arm overlapped with those of the control arm, indicating a
lack of significant difference, and it was not possible to make direct
comparisons (number needed to treat, number needed to harm)
because comparator arms include other active therapies as well as
placebo.67 The effect size seen was much less than that in patients with
noncancer neuropathic pain.20
There are limited data on treatment that is effective for neuro-
pathic pain related to cancer treatment. A recent RCT explored the use
of duloxetine 60 mg, an antidepressant from the selective serotonin
and noradrenaline reuptake inhibitor class, for chemotherapy-
induced painful peripheral neuropathy; it showed a mean decrease in
average pain on an 11-point numeric rating scale of 1.06 (95% CI, 0.72
to 1.4) in the duloxetine group versus 0.34 (95% CI, 0.01 to 0.66; P 
.003) in the placebo group after 5 weeks of treatment.69
BISPHOSPHONATES
Bone metastases, a common source of pain, are caused by up-
regulated osteoclastic activity, leading to increased bone resorption.
Bisphosphonates are selective inhibitors of osteoclastic bone resorp-
tion. There are two classes of bisphosphonates—the older simple
bisphosphonates, such as etidronate and clodronate, and the more
potent inhibitors of bone resorption, the nitrogen-containing bispho-
sphonates, which include pamidronate and zoledronate. Several
meta-analyses have shown a decrease in skeletal-related events with
bisphosphonates, and the evidence is strongest for breast cancer,74
prostate cancer,75 and multiple myeloma.76 A Cochrane review re-
ported a reduction in skeletal-related events of 15% (risk ratio, 0.85;
95% CI, 0.77 to 0.94; P  .001) in nine studies including 2,806 patients
with breast cancer with bone metastases that compared a bisphospho-
nate with either placebo or no bisphosphonate.74 A significant im-
provement in bone pain was found after receiving a bisphosphonate in
six of 11 studies that evaluated pain. A meta-analysis of eight studies
comparing a bisphosphonate with placebo found minimal differences
in adverse events between the two groups, but there was an increase in
nausea and acute-phase reactions in the bisphosphonate arms.75 The
risk of osteonecrosis of the jaw is estimated to be between 0.7% and
12% and is more likely to occur in patients with metastatic disease and
with poor oral hygiene or after dental surgery74 (Table 5).
DENOSUMAB
Denosumab is a fully human monoclonal antibody against the cyto-
kine receptor-activated nuclear B ligand (RANKL), which is in-
volved in tumor cell migration and is a mediator of osteoclast
differentiation and activation.23 Six RCTs in patients with bone me-
tastases found a benefit for denosumab over zoledronic acid,
pamidronate, or ibandronate in incidence (risk ratio, 0.84; 95% CI,
0.80 to 0.88) and time to skeletal-related events, but no difference in
overall survival,77 although subgroup analysis in one study suggested
that patients with multiple myeloma may have increased mortality
with denosumab.78 Total adverse events were similar, except for in-
creased hypocalcemia and less nephrotoxicity with denosumab. One
of the studies, in which pain was a secondary outcome, randomly
assigned 2,046 women with breast cancer with bone metastases to
denosumab or zoledronic acid. The study reported no meaningful
difference in improvement in pain severity or time to improvement of
pain between the groups, but there was less worsening of pain severity
and less functional impairment secondary to pain and fewer patients
required progression to strong opioid analgesics in the denosumab
arms73 (Table 5).
These studies suggest that bisphosphonates are beneficial as an
adjunct for pain control from bony metastases for some tumor types.
Denosumab is more convenient than bisphosphonates but substan-
tially more expensive.
LIGNOCAINE (LIDOCAINE)
Local anesthetics inhibit pain predominantly by blocking sodium
channels and have shown efficacy in chronic nonmalignant neuro-
pathic pain.21 Topical lignocaine has shown benefit in allodynia from
postherpetic neuralgia.22 There are some uncontrolled and controlled
studies of continuous subcutaneous infusion of lignocaine in cancer
pain79-81 (Table 6). However, these studies all have methodologic
limitations, and the role of lignocaine needs to be substantiated in
randomized placebo-controlled studies.
KETAMINE
The dissociative anesthetic ketamine has been used widely in the
management of chronic cancer pain, usually in the setting of pain that
is not controlled by opioids or opioids plus adjuvant analgesics.24 Its
use had been mainly extrapolated from surgical settings, and evidence
for benefit has come mainly from case series and uncontrolled studies
in people with cancer (Table 6). However, in a recent RCT, there was
no difference compared with placebo, pain type (neuropathic v noci-
ceptive) was not a predictor of response, and those receiving ketamine
were more likely to experience adverse effects.24 This study was not
powered to specifically compare differences in effect between neuro-
pathic and nociceptive pain.
CANNABINOIDS
Some cultural groups have used cannabinoids for medicinal purposes
for thousands of year. There is a lack of evidence for their efficacy for
cancer pain, particularly compared with other agents,82 but trials
are ongoing.
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LIMITATIONS OF CURRENT DATA
The evidence for use of nonopioid analgesia in cancer pain remains
limited. With the exception of the bisphosphonate/denosumab trials,
most studies have small sample sizes, frequently have methodologic
limitations, and lack long-term follow-up, so that data on the effects of
chronic use of most of the agents remain limited.
RECOMMENDATIONS FOR FUTURE RESEARCH
Some of the outstanding questions include the following: whether
acetaminophen should be used concurrently with an opioid and, if so,
in what dose; whether NSAIDs and corticosteroids can be safely con-
tinued long term in patients with cancer and the safety and efficacy of
the selective COX-2 inhibitors still on the market; and which nonopi-
oid analgesics are best for specific types of pain and in which combi-
nations. Pharmacogenomics and phase IV studies may have a role to
play in answering these questions.
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